Previous 10 | Next 10 |
RESEARCH TRIANGLE PARK, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™ today announced it will report second quarter 2022 financial results before the market opens on Thursday, August 11, 2022. Company mana...
The following slide deck was published by Science 37 Holdings, Inc. in conjunction with this event. For further details see: Science 37 Holdings (SNCE) Investor Presentation - Slideshow
RESEARCH TRIANGLE PARK, N.C., June 15, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today published new data from oncology clinical research executives, indicating three-quarters of all planned new oncology study start...
RESEARCH TRIANGLE PARK, N.C., June 07, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the following virtual investor conferences. Lytham Partners Summer 2022 I...
RESEARCH TRIANGLE PARK, N.C., May 25, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the company will be participating in the upcoming William Blair Growth Stock Conference in Chicago. Science 37...
RESEARCH TRIANGLE PARK, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today introduced a rapid-deployment virtual site model for slow enrolling clinical trials to access patients beyond the existing site-b...
RESEARCH TRIANGLE PARK, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today introduced a milestone technology release, setting the bar as the most comprehensive, end-to-end platform to fully orchestrate st...
Science 37 Holdings, Inc. (SNCE) Q1 2022 Earnings Conference Call May 9, 2022 08:00 ET Company Participants Caroline Paul - Investor Relations David Coman - Chief Executive Officer Mike Zaranek - Chief Financial Officer Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Ju...
The following slide deck was published by Science 37 Holdings, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Science 37 Holdings, Inc. 2022 Q1 - Results - Earnings Call Presentation
Science 37 press release (NASDAQ:SNCE): Q1 GAAP EPS of $0.35 beats by $0.61. Revenue of $18.69M (+50.2% Y/Y) beats by $3.63M. The company is reaffirming FY2022 revenue guidance of $86M to $96M vs. consensus of $91.13M. David Coman, Chief Executive Officer of Science 37 said, "With our sales p...
News, Short Squeeze, Breakout and More Instantly...
Science 37 Holdings Inc. Company Name:
SNCE Stock Symbol:
NASDAQ Market:
Science 37 Holdings Inc. Website:
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed ...
RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37 , a leader in enhancing patient access to clinical trials, has been added to over 20 studies that were lagging in recruitment, helping them to trend back towards their projected targets. Leveraging its proprietary ...
RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Science 37, Inc., please note that the first sentence of the second paragraph has been revised. The corrected release follows: Science 37 Holdings, Inc. , a lea...